From 4198193303075f6c36536a44e48c7d7c08111e11 Mon Sep 17 00:00:00 2001 From: j Date: Thu, 18 Jun 2026 15:09:52 +0700 Subject: [PATCH] evidence: source inventory for hypertension-control-global literature-scout source-inventory task. Adds 6 dated, classified evidence records (usable/limited/rejected) with measured-BP discipline: - NCD-RisC Lancet 2021 pooled analysis (usable backbone) - WHO STEPS microdata (usable) - DHS Program biomarkers (limited) - GBD 2021 high-SBP burden (limited) - PURE study JAMA 2013 (limited) - self-report bias study (rejection rule for self-report-only surveys) Also fixes a rotted URL in the pre-existing who-hypertension-2023 record (404 -> stable WHO IRIS handle) and refreshes its access date. Updates datasets.md and evidence.md to match. Satisfies done_condition: >=4 sources classified with explicit reasons covering measure family, timing, geographic grain, and linkage relevance. --- .../hypertension-control-global/datasets.md | 28 +++- .../hypertension-control-global/evidence.json | 121 +++++++++++++++++- .../hypertension-control-global/evidence.md | 24 ++++ 3 files changed, 163 insertions(+), 10 deletions(-) diff --git a/problem-packs/public-health/hypertension-control-global/datasets.md b/problem-packs/public-health/hypertension-control-global/datasets.md index fa4ee27..8d72b2a 100644 --- a/problem-packs/public-health/hypertension-control-global/datasets.md +++ b/problem-packs/public-health/hypertension-control-global/datasets.md @@ -1,15 +1,29 @@ # Dataset Inventory -| Source | Grain | Status | Use | -| ---------------------------- | ------------ | ------ | ------------- | -| Primary survey data | Sub-national | Usable | Core analysis | -| Satellite/environmental data | Variable | Usable | Risk context | -| Population data | 100m | Usable | Denominator | +Dated source inventory for hypertension detection and control gaps in LMICs. Classification reflects fitness for a sub-national detection-treatment-control cascade analysis. Inventory compiled 2026-06-18. + +## Sources + +| Source | Grain | Measure family | Status | Use | +| ---------------------------------------- | --------------------------------- | --------------------------------------- | -------- | ---------------------------------------------- | +| WHO Global Report on Hypertension (2023) | Global / national | Modeled cascade benchmark | Usable | Global benchmark for diagnosis/control rates | +| NCD-RisC pooled analysis (Lancet 2021) | National, ages 30-79 | Measured-BP cascade by country and sex | Usable | Cross-country comparison backbone | +| WHO STEPS microdata (NCD Microdata Repo) | National; limited sub-national | Measured-BP survey microdata | Usable | Country cascade estimates from raw survey data | +| DHS Program biomarkers | National + georeferenced clusters | Measured-BP prevalence (subset) | Limited | Supplementary prevalence where BP was measured | +| GBD 2021 high systolic BP burden (IHME) | National + some subnational | Modeled attributable burden (DALYs) | Limited | Burden context, not a cascade measurement | +| PURE study (JAMA 2013) | Community cohorts, ages 35-70 | Measured-BP cascade, non-representative | Limited | Historical cross-income comparison only | +| Self-report-only household surveys | Varies | Self-reported diagnosis | Rejected | Underestimates measured prevalence (see below) | + +## Classification Reasons + +- **Usable** sources provide directly measured blood pressure and a detection/treatment/control cascade at national or finer grain. +- **Limited** sources are usable only for a narrower purpose: DHS BP coverage is survey-specific and cascade items are inconsistent; GBD outputs are attributable burden, not measured control; PURE is non-representative community cohorts from 2003-2009. +- **Rejected**: self-report-only surveys underestimate measured prevalence by ~20% (women) to ~55% (men) per a large Indian comparison study (SSM - Population Health, 2022), so they cannot anchor prevalence or cascade estimates. ## Required Properties -Source methodology, data year, geographic grain, license. +Source methodology, data year, geographic grain, measure family (measured vs self-reported), license, and detection/treatment/control coverage. ## Rejection Rule -Rejected if methodology, grain, date, or license unverifiable. +Rejected if methodology, grain, date, or license is unverifiable, or if hypertension status is self-reported rather than measured. diff --git a/problem-packs/public-health/hypertension-control-global/evidence.json b/problem-packs/public-health/hypertension-control-global/evidence.json index 1f9d830..b55aa27 100644 --- a/problem-packs/public-health/hypertension-control-global/evidence.json +++ b/problem-packs/public-health/hypertension-control-global/evidence.json @@ -5,16 +5,131 @@ "claim": "WHO estimates 1.3 billion adults have hypertension, with only 45 percent diagnosed and 20 percent controlled globally, and control rates below 10 percent in most LMICs.", "evidence_type": "primary-source", "source": { - "title": "Global Report on Hypertension", - "url": "https://www.who.int/publications/i/item/9789240081060" + "title": "Global report on hypertension: the race against a silent killer", + "url": "https://iris.who.int/handle/10665/372896" }, "source_date": "2023-09-19", - "access_date": "2026-06-07", + "access_date": "2026-06-18", "method": "Reviewed WHO hypertension report, detection and control cascade data.", "limitations": [ "Diagnosis data depends on survey frequency.", "Treatment-control data from routine systems is incomplete." ], "confidence": "high" + }, + { + "id": "ncd-risc-hypertension-trends-2021", + "problem_id": "public-health/hypertension-control-global", + "claim": "A pooled analysis of 1201 population-representative studies with measured blood pressure (104 million participants, 184 countries) estimates age-standardized hypertension prevalence, detection, treatment, and control for adults aged 30-79 by country and sex for 1990-2019, and is usable as the cross-country comparison backbone for this pack.", + "evidence_type": "peer-reviewed-study", + "source": { + "title": "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants", + "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8446938/" + }, + "source_date": "2021-09-11", + "access_date": "2026-06-18", + "method": "Read the open-access NCD-RisC article and its methods section; confirmed it uses only measured (not self-reported) blood pressure and reports the full detection-treatment-control cascade by country, sex, and year.", + "limitations": [ + "Estimates are at national level for ages 30-79 only; the paper does not provide sub-national grain.", + "Where country data are sparse the cascade values are modeled, widening uncertainty for many low-income countries.", + "Cut-off is 2019, so it predates recent program scale-up." + ], + "confidence": "high" + }, + { + "id": "who-steps-microdata", + "problem_id": "public-health/hypertension-control-global", + "claim": "The WHO NCD Microdata Repository distributes nationally representative STEPS survey microdata with directly measured blood pressure, supporting country-level detection, treatment, and control estimates and limited sub-national breakdowns where sample design allows.", + "evidence_type": "dataset", + "source": { + "title": "WHO NCD Microdata Repository — STEPS collection", + "url": "https://extranet.who.int/ncdsmicrodata/index.php/collections/STEPS" + }, + "source_date": "2024-01-01", + "access_date": "2026-06-18", + "method": "Opened the STEPS collection in the WHO NCD Microdata Repository and confirmed it lists country STEPS datasets with measured blood pressure variables and downloadable microdata under request-based access.", + "limitations": [ + "Surveys are cross-sectional and run infrequently, so a country may have only one usable year.", + "Sampling is designed for national estimates; sub-national power is uneven and often insufficient.", + "Field BP measurement protocol (single visit, device) differs from clinical diagnosis, so control status is approximate.", + "Source date is approximate — the collection is continuously updated rather than published once." + ], + "confidence": "high" + }, + { + "id": "dhs-program-biomarkers", + "problem_id": "public-health/hypertension-control-global", + "claim": "The DHS Program measures blood pressure as a biomarker for women and men aged 15 and over in selected surveys, providing an additional source of measured-BP prevalence with georeferenced clusters in some LMICs.", + "evidence_type": "dataset", + "source": { + "title": "The DHS Program — Biomarkers", + "url": "https://www.dhsprogram.com/What-We-Do/Biomarkers.cfm" + }, + "source_date": "2024-01-01", + "access_date": "2026-06-18", + "method": "Reviewed the DHS biomarkers page and confirmed blood pressure is among collected biomarkers for ages 15+; cross-checked that BP is a recent and survey-specific addition, not universal across all DHS rounds.", + "limitations": [ + "Blood pressure is collected only in a subset of DHS surveys and countries, not all rounds.", + "Treatment and control cascade items are not consistently captured, so DHS is stronger for prevalence than for control.", + "Source date is approximate — this is a continuously maintained program page, not a dated publication." + ], + "confidence": "medium" + }, + { + "id": "gbd-2021-high-sbp-burden", + "problem_id": "public-health/hypertension-control-global", + "claim": "GBD 2021 (IHME) provides modeled estimates of deaths and DALYs attributable to high systolic blood pressure by country, sex, age, and selected subnational units for 1990-2021, usable as a burden-context layer but not as a direct detection-treatment-control measurement.", + "evidence_type": "dataset", + "source": { + "title": "Global Burden of Disease Study 2021 (GBD 2021) Burden and Strength of Evidence by Risk Factor 1990-2021", + "url": "https://ghdx.healthdata.org/record/ihme-data/gbd-2021-burden-by-risk-1990-2021" + }, + "source_date": "2024-05-18", + "access_date": "2026-06-18", + "method": "Opened the GHDx record for the GBD 2021 risk-factor burden product and confirmed it covers high systolic blood pressure attributable burden with subnational coverage for a subset of countries.", + "limitations": [ + "Outputs are attributable burden (deaths, DALYs), not measured detection, treatment, or control rates.", + "Values are modeled estimates with uncertainty intervals, not survey observations.", + "Subnational estimates exist only for a subset of countries." + ], + "confidence": "medium" + }, + { + "id": "pure-study-hypertension-2013", + "problem_id": "public-health/hypertension-control-global", + "claim": "The PURE study reported hypertension prevalence, awareness, treatment, and control across high-, middle-, and low-income countries using measured blood pressure in 142042 adults aged 35-70 from 628 communities, documenting markedly lower control in lower-income settings.", + "evidence_type": "peer-reviewed-study", + "source": { + "title": "Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries (PURE)", + "url": "https://pubmed.ncbi.nlm.nih.gov/24002282/" + }, + "source_date": "2013-09-04", + "access_date": "2026-06-18", + "method": "Read the PubMed record and abstract to confirm cohort size, age range, country mix, and that the cascade was based on measured blood pressure.", + "limitations": [ + "Sample is community cohorts, not nationally representative, so country estimates are not generalizable.", + "Age range is restricted to 35-70 years.", + "Data were collected 2003-2009, so figures are dated relative to current control programs." + ], + "confidence": "medium" + }, + { + "id": "self-report-hypertension-bias-2022", + "problem_id": "public-health/hypertension-control-global", + "claim": "Self-reported hypertension diagnosis underestimates measured prevalence by roughly 20 percent in women and 55 percent in men in a large Indian survey, which is the documented basis for rejecting self-report-only household surveys as a prevalence source for this pack.", + "evidence_type": "peer-reviewed-study", + "source": { + "title": "Inconsistency in prevalence of hypertension based on self-reports and use of standard tests: Implications for large scale surveys", + "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9547289/" + }, + "source_date": "2022-10-03", + "access_date": "2026-06-18", + "method": "Read the open-access article and its results to confirm the direction and magnitude of self-report bias against standard measured tests, then applied it as the rejection rule for self-report-only sources.", + "limitations": [ + "Quantified bias is from India and may differ in magnitude elsewhere.", + "The study justifies rejecting self-report for prevalence; it is not itself a usable cross-country data source.", + "It does not address treatment or control measurement specifically." + ], + "confidence": "high" } ] diff --git a/problem-packs/public-health/hypertension-control-global/evidence.md b/problem-packs/public-health/hypertension-control-global/evidence.md index 40d96d3..115a3a2 100644 --- a/problem-packs/public-health/hypertension-control-global/evidence.md +++ b/problem-packs/public-health/hypertension-control-global/evidence.md @@ -6,6 +6,30 @@ WHO estimates 1.3 billion adults have hypertension, with only 45 percent diagnosed and 20 percent controlled globally, and control rates below 10 percent in most LMICs. +### ncd-risc-hypertension-trends-2021 + +NCD-RisC pooled 1201 measured-BP studies across 184 countries to estimate the detection-treatment-control cascade for ages 30-79 by country and sex, 1990-2019. Usable as the cross-country backbone; national grain only and modeled where data are sparse. + +### who-steps-microdata + +The WHO NCD Microdata Repository distributes STEPS survey microdata with directly measured blood pressure. Usable for country cascade estimates; sub-national power is uneven and surveys are infrequent. + +### dhs-program-biomarkers + +The DHS Program measures blood pressure for ages 15+ in selected surveys, with georeferenced clusters. Limited: BP coverage is survey-specific and treatment/control items are inconsistent. + +### gbd-2021-high-sbp-burden + +GBD 2021 (IHME) supplies modeled deaths and DALYs attributable to high systolic blood pressure, with some subnational coverage. Limited: it is attributable burden, not a measured detection-treatment-control cascade. + +### pure-study-hypertension-2013 + +PURE reported the measured-BP cascade across income groups in 142042 adults aged 35-70 from 628 communities. Limited: non-representative community cohorts, restricted ages, data from 2003-2009. + +### self-report-hypertension-bias-2022 + +A large Indian comparison found self-report underestimates measured hypertension by ~20% (women) to ~55% (men). Basis for rejecting self-report-only household surveys as a prevalence source. + ## Evidence Quality Rule Evidence accepted only when source, method, limitations, and confidence are explicit enough for a reviewer to attack.